ATLANTA – Emory University Healthcare has achieved a significant milestone by becoming the first medical team in the United States to successfully implant a new experimental heart pump, known as …
-
-
Atrial tachycardia (AT) is a type of arrhythmia originating from the atria of the heart. It is characterized by a rapid and abnormal heart rhythm that originates from an ectopic …
-
Supraventricular tachycardia (SVT) is a condition characterized by an abnormally fast heart rate originating from the upper chambers of the heart. This rapid heartbeat can lead to various symptoms, including …
-
New research indicates that cryoablation is a safe and effective method for closing a congenital patent foramen ovale (PFO)—a small hole in the heart—in patients with atrial fibrillation (AF) undergoing …
-
Heart failure (HF) is a complex clinical syndrome characterized by the heart’s inability to pump sufficient blood to meet the body’s needs. One of the lesser-known but significant complications of …
-
Boehringer Ingelheim, a leader in animal health, has introduced VETMEDIN Solution, the first oral solution approved by the U.S. Food and Drug Administration (FDA) for managing congestive heart failure (CHF) …
-
CARMAT Hosts Successful Inaugural “Aeson® European User Meeting” to Advance Deployment of Artificial Heart. CARMAT, the designer and developer of the Aeson® artificial heart, successfully held its first “Aeson® European …
-
Lupin Pharmaceuticals Recalls Over 600,000 Bottles of Hypertension Medication in the U.S., Reports USFDA. Lupin Pharmaceuticals is recalling over 600,000 bottles of a high blood pressure medication in the United …
-
Orthostatic hypertension, also known as postural hypertension, is a condition characterized by a significant rise in blood pressure when a person transitions from a lying or sitting position to a …
-
The U.S. Food and Drug Administration (FDA) has approved Acoramidis (brand name Attruby), marking it as the first “near-complete” stabilizer for treating transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, announced late …
Advertisements